Swiss Electric Utilities Stock News

Earlier this month, Novartis received traditional FDA approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression, upgrading its earlier accelerated approval that was based on proteinuria reduction. The decision is grounded in two-year Phase III data showing Fabhalta’s first-in-class oral complement inhibition meaningfully slowed estimated glomerular filtration rate decline versus placebo, reinforcing...

SoftwareOne Holding (SWX:SWON) is entering a new chapter after the board decided that Raphael Erb will move from Co-CEO to sole CEO from 1 August 2026, following Melissa Mulholland’s departure. See our latest analysis for SoftwareOne Holding. At a share price of CHF8.22, SoftwareOne Holding has seen a 15.69% 90 day share price return and a 20.85% 1 year total shareholder return, while longer term total shareholder returns have been weak. This suggests recent momentum has picked up as...

What ABB’s latest results and guidance tell you ABB (SWX:ABBN) has drawn fresh attention after reporting second quarter 2026 results, updating its share buyback, and issuing guidance that outlines expected growth in comparable revenues and a positive book to bill ratio. For the quarter ended June 30, 2026, ABB reported revenue of US$9,475 million compared with US$8,295 million a year earlier. Net income was US$1,231 million, while basic earnings per share from continuing operations came in at...

Mikron Holding (SWX:MIKN) opened H1 2026 with revenue of CHF 180.5 million and basic EPS of CHF 0.83, while trailing twelve month revenue stood at CHF 370.6 million with basic EPS of CHF 1.68. This provides a clear snapshot of the company’s recent earnings power. Over the last three reported halves, revenue has ranged between CHF 180.5 million and CHF 191.9 million, with basic EPS moving between CHF 0.83 and CHF 1.10. This gives investors a tight read on how the top line and EPS have tracked...

Sandoz Group (SWX:SDZ) drew investor attention after announcing multiple leadership changes, including appointing Pascal Bouye to lead Generics Manufacturing & Supply and expanding M&A responsibilities for North America head Keren Haruvi. See our latest analysis for Sandoz Group. Sandoz Group’s latest executive reshuffle comes as the stock trades at CHF65.74, with the share price up 14.89% year to date and the 1 year total shareholder return at 45.41%. This suggests that momentum has eased in...

Europe’s growth story is increasingly shaped by companies tied to powerful themes like AI, automation, and digitalisation, and ASML is at the center of that conversation. Its recent Q2 update, with €9.3b in sales and 91 lithography systems sold, underlines how strongly AI-related demand is feeding into parts of the market. But a forward P/E near 50 also shows how quickly expectations can stretch. This article looks at three European Growth Stocks that are exposed to the same news backdrop as...

Swisscom (SWX:SCMN) is in focus after partnering with Sunrise to form a fraud risk consortium, using shared real time risk signals to help block cross carrier attacks and strengthen digital onboarding safeguards. See our latest analysis for Swisscom. Against this backdrop of tighter fraud controls, Swisscom’s share price is CHF634.0, with a 1 day share price return of 1.44% and a year to date share price return of 9.50%. The 1 year total shareholder return of 17.93% suggests momentum has been...

Regulators in the United States and European Union have widened access to several gene therapies, with the European Commission approving Novartis (SWX:NOVN) product onasemnogene abeparvovec for a broader group of patients with 5q spinal muscular atrophy. See our latest analysis for Novartis. Against this backdrop, Novartis shares are trading at CHF123.26, with a 30 day share price return of 2.97% and year to date share price return of 13.60%. The 1 year total shareholder return of 36.07%...

Alcon (SWX:ALC) is back in focus after announcing a non-exclusive collaboration with RxSight to co-develop adjustable presbyopia-correcting intraocular lenses. These lenses can be fine tuned after cataract surgery. See our latest analysis for Alcon. At a share price of CHF56.94, Alcon has seen short term momentum pick up, with a 1 month share price return of 8.42% and 7 day gain of 5.37%. However, the 1 year total shareholder return is down 17.89%, pointing to ongoing investor caution even as...

As geopolitical tensions and energy market volatility continue to influence the European markets, the pan-European STOXX Europe 600 Index recently experienced a decline of 1.79%. In this fluctuating environment, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to navigate these uncertain times.

Why analyst sentiment around ams-OSRAM stock just shifted Recent analyst upgrades and higher earnings estimates have put ams-OSRAM (SWX:AMS) back on many investors’ radar, as the stock’s performance and sentiment move in tandem with these revised expectations. See our latest analysis for ams-OSRAM. ams-OSRAM’s CHF18.69 share price reflects a mixed recent pattern, with the stock down 3.16% on a 1 day share price return and 4.89% on a 30 day share price return, yet still showing a 61.40% 90 day...

In July 2026, Roche Holding received US FDA Priority Review for Gazyva/Gazyvaro in primary membranous nephropathy, a condition with no FDA approved therapies. Roche also launched the cobas HDV test, described as the first fully automated, high throughput diagnostic assay for Hepatitis D Virus. Both developments add to Roche Holding's immunology and virology portfolio and target areas with significant unmet medical need. For investors tracking Roche Holding (SWX:ROP), these July 2026...

Amidst geopolitical tensions and energy market volatility, the European stock market has faced challenges, with the pan-European STOXX Europe 600 Index recently experiencing a decline. Despite these uncertainties, dividend stocks remain an attractive option for investors seeking steady income streams in fluctuating markets. A strong dividend stock typically combines reliable payouts with a resilient business model that can withstand economic pressures and adapt to changing conditions.

In July 2026, Genpact announced it had partnered with Nestlé Business Solutions to build a new AI-enabled Global Capability Center in Hyderabad, India, while Nestlé also began tailoring recipes for GLP-1 users and launched its SparX Innovation Hub in Dubai to speed AI-driven product development in the MENA region. Together, these moves highlight how Nestlé is pairing process automation with rapid, data-led product innovation to respond more precisely to evolving health-focused consumer...

Julius Bär Gruppe (SWX:BAER) has drawn investor attention after appointing Peter Burrill as Chief Financial Officer and Executive Board member, replacing Evie Kostakis. His start is planned for August 2026, pending regulatory clearance. See our latest analysis for Julius Bär Gruppe. At a share price of CHF74.72, Julius Bär Gruppe has seen firm momentum recently, with a 30 day share price return of 15.49% and a 90 day share price return of 20.52%, while the 1 year total shareholder return of...

As geopolitical tensions and energy market volatility weigh on European markets, the STOXX Europe 600 Index recently saw a decline, reflecting investor concerns over potential inflationary pressures and monetary policy adjustments. Amidst this backdrop, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

As geopolitical tensions and energy market volatility weigh on European equities, the pan-European STOXX Europe 600 Index has experienced a notable decline. Amidst these market dynamics, dividend stocks can offer investors a measure of stability and income potential, making them an attractive option in uncertain times.

As geopolitical tensions and energy market volatility shape the European financial landscape, investors are closely monitoring how these factors influence inflation and monetary policy expectations. Amidst this backdrop, growth companies with high insider ownership can offer unique insights into potential resilience and strategic alignment with shareholder interests.

A “super” El Niño expected in 2026–27 could rattle food supplies, push key crop prices sharply higher, and keep inflation pressure in play for years. For investors, that kind of shock can hurt some stocks tied to food and commodities while creating openings in others that are better positioned for price spikes and volatility. This article looks at three stocks that are closely exposed to the El Niño news, with one that could benefit from the setup and two where the risks may be more...

Cembra Money Bank has recently overhauled its organisation, creating a new Sales division, a Corporate Functions division and reshaping executive roles, including appointing a Chief Sales Officer and combining the CFO and Chief Risk Officer responsibilities. By consolidating core commercial activities and elevating compliance as an independent function, the bank is signalling a stronger push for integrated customer service while preserving an emphasis on risk and control. We’ll now examine...

Logitech International S.A. recently announced it became the Official PC Peripheral Partner for Call of Duty: Modern Warfare 4, integrating Logitech G mice, keyboards, headsets, in-game items, and creator tools into the franchise’s ecosystem. The partnership extends beyond branding, tying Logitech G hardware, Streamlabs-powered creator experiences, and LIGHTSYNC RGB integrations directly into Modern Warfare 4’s “Play for Prestige” campaign, which could deepen gamer engagement with the...

In July 2026, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by nearly 2% amid easing inflation concerns and stable unemployment rates. As investors navigate these conditions, growth companies with high insider ownership can present compelling opportunities due to their potential alignment of management interests with shareholders and the ability to capitalize on favorable economic developments.

As the pan-European STOXX Europe 600 Index recently advanced by 1.96%, bolstered by lower oil prices and easing inflation expectations, investor sentiment in Europe appears cautiously optimistic. In this environment, identifying undervalued stocks becomes crucial, as these opportunities may offer potential for growth when market conditions stabilize further.

Client win puts Bachem Holding in focus ImmuPharma PLC has appointed Bachem Holding (SWX:BANB) subsidiary Bachem AG to manufacture the active pharmaceutical ingredient for its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for the project. The collaboration positions Bachem Holding within the next stage of Kapiglucagon development, with work initially centered on the active ingredient before ImmuPharma selects a separate partner for drug product...